iiinova — where your digital self keeps evolving

ADA Professional Publications @adapubs.bsky.social · 3h

Microgel technology could offer a more favorable risk-benefit profile by reducing infection risks, organ toxicity, and tumorgenicity associated with the use of systemic immunosuppression. Read here ➡️ doi.org/10.2337/db26-0280

Diagram illustrating a scientific process to enhance islet function and viability. The left section shows prosurvival molecules and immunomodulatory properties, leading to recruitment of T regulatory cells. The middle section features engineered microgels with SA-protein protecting co-transplanted islets. The right section depicts the reduction of cytotoxic T cells and increase in T regulatory cells, highlighting improved islet function. Arrows indicate the flow of the process across the sections.

000

ADA Professional Publications @adapubs.bsky.social · 6h

Weekly blood ketone tests over one month can predict DKA risk in next month as accurately as twice-weekly checks. This approach reduces testing burden while maintaining clinical predictive power. Read here ➡️ doi.org/10.2337/dc26-1110

This image is a research poster titled "The Minimum Frequency of Well-Day Capillary Blood Ketone Testing Needed to Predict 1-Month Diabetic Ketoacidosis Risk in Type 1 Diabetes." It contains four sections: Aim, Study Population, Results, and Implications. The Aim notes the investigation of blood ketone testing frequency for predicting diabetic ketoacidosis risk. The Study Population uses data from EASE 2 and 3 trials with 1,410 participants. Results are shown in a graph, indicating that biweekly ketone testing matches the predictive accuracy of daily testing. The Implications suggest that less frequent testing can potentially enhance adherence without reducing performance.

000

ADA Professional Publications @adapubs.bsky.social · 10h

🚨 New journal, new #podcast. The Points of CARE covers highlights in each issue of DOCM CARE. 🎧 thepointsofcare.libsyn.com 📚 diabetesjournals.org/docm-care In this ep: ✨ Variability in Autoantibody Ordering Patterns ✨Cognitive Change in Older Adults With T1D ✨& more!

010

ADA Professional Publications @adapubs.bsky.social · 08/10/2026

This scientific statement supports diabetes technology use in the primary care setting. Team-based models and virtual support can expand access and advance equitable diabetes care. Read here ➡️ doi.org/10.2337/doci26-0005

Diagram illustrating steps to integrate diabetes technology into primary care. It starts with designating a diabetes technology champion, then assessing team capacity. Based on the assessment, options include training existing team, leveraging a trained interdisciplinary team, or referring to external resources. Ends with diabetes technology integration into primary care.

000

ADA Professional Publications @adapubs.bsky.social · 08/10/2026

#DiGest Follow-Up: In #GDM, late-pregnancy energy restriction or modest weight loss showed no harm to infant growth to 1 year, and weight loss was linked to lower LGA risk and fat mass at 3 months. Read here ➡️ doi.org/10.2337/dc26-0405

The image is an infographic titled "DiGest: the Follow-up Study," supported by Diabetes UK. It is divided into three sections: Methods, Results, and Conclusions. 1. Methods: A study involving 425 pregnant individuals with gestational diabetes and pre‑pregnancy BMI ≥ 25 kg/m². They were randomized into two groups: reduced energy (1,200 kcal/day) and standard energy (2,000 kcal/day). 2. Results: Highlights findings on weight loss during pregnancy and its effects on maternal and infant outcomes. Weight loss was associated with lower maternal weight at 3 months, but not at 12 months postpartum. Infant weight was not affected at 2 months postpartum. 3. Conclusions: Suggests energy restriction or modest weight loss in pregnancy did not affect the infant’s growth or the likelihood of growth abnormalities in early life.

010

ADA Professional Publications @adapubs.bsky.social · 08/10/2026

👀 The latest issue of Diabetes, Obesity, and CardioMetabolic CARE (DOCM CARE), the new ADA journal focused on comprehensive, person-centered care, is live. 🔗 diabetesjournals.org/docm-care Featuring: ✨ Cognitive Change & T1D ✨ School Meals & Prediabetes ✨ & more!

The Sept/Oct DOCM cover, featuring digital art, "Individuation," by Linda Kramer.

000

ADA Professional Publications @adapubs.bsky.social · 07/10/2026

This retrospective study found that excess risk of mortality, cardiovascular events, and end-stage kidney disease was lower with older ages at #T1D diagnosis. Read here ➡️ doi.org/10.2337/dc26-0200

This infographic presents a study on type 1 diabetes, examining how age at diagnosis affects mortality and complications. The context section explains it used data from the Swedish National Diabetes Register, focusing on mortality and cardiovascular and kidney outcomes. The key findings section shows that each 1-year increase in diagnosis age lowers mortality risk by 1.7%, with specific reductions in acute myocardial infarction, heart failure, diabetic nephropathy, and end-stage kidney disease.

000

ADA Professional Publications @adapubs.bsky.social · 07/10/2026

Adherence to Life’s Essential 8 is associated with a lower risk for mild cognitive impairment and dementia in people with diabetes, even accounting for genetic risk. Read here ➡️ doi.org/10.2337/dc25-3126

Infographic titled "The Joint Effects of Life’s Essential 8 and Genetics on Mild Cognitive Impairment and Dementia Risk in People With Diabetes." It includes a pie chart showing percentages of diabetes prevalence across different ethnicity groups. Methods include various health metrics and genetic risk scores. Key findings highlight the association between Life's Essential 8 (LE8), cognitive health, and brain structure alterations. An objective and conclusion summarize the study's focus and outcomes.

000

ADA Professional Publications @adapubs.bsky.social · 06/10/2026

Among older adults with longstanding #T1D, nearly two-thirds had intermediate or greater risk of obstructive sleep apnea and over 40% reported poor sleep quality. 😴 Read here ➡️ doi.org/10.2337/dc26-1678

The image is an infographic about the increased risks of poor sleep quality and excessive daytime sleepiness among older adults with Type 1 Diabetes. It displays data from the DCCT/EDIC study of 963 adults aged 48 to 79, where 67% had intermediate or greater OSA risk, 43% had poor sleep quality, and 22% experienced excessive daytime sleepiness. For each 1% increase in HbA1c, the risk of sleep-related problems reportedly increased by 15-20% for current and 40-year mean exposure, adjusted for age, sex, and BMI. Further assessments and objective measures of sleep-related problems are warranted due to many unrecognized cases.

000

ADA Professional Publications @adapubs.bsky.social · 06/10/2026

Central PDE4 inhibition promotes brown adipose tissue thermogenic activity and contributes to the metabolic effects of rolipram. Read here ➡️ doi.org/10.2337/db25-1135

A diagram illustrates a scientific experiment. A mouse is depicted connected via a tube to a syringe labeled "Rolipram." The mouse's brain and brown adipose tissue are highlighted. The brain's phosphodiesterase 4 is marked, indicating a pathway to increased UCP1, temperature, and energy expenditure. Another syringe is labeled "YM-976.

000

ADA Professional Publications @adapubs.bsky.social · 06/10/2026

🚨 NEW DOC Updates #podcast You know how GLP-1s impact diabetes & weight loss. But what about coronary disease treatment? Liver disease? Heart failure? In this special ep, we explores the latest in incretin biology. 👂Listen: diabetesjournals.org/journals/pages/podcasts_incretin_biology

020

ADA Professional Publications @adapubs.bsky.social · 06/10/2026

HTD1801, a first-in-class, novel therapy, significantly reduced HbA1c and improved cardiometabolic and inflammatory markers in participants with #T2D. Read here ➡️ doi.org/10.2337/dc26-0739

The image is an infographic detailing the effects of HTD1801 on type 2 diabetes markers. It includes sections on objective, study design, results, and conclusion. A graph shows a decrease in HbA1c levels over time. Key measurements include glucose metabolism (HbA1c, FPG), lipid metabolism (non-HDL-c), and inflammation (hs-CRP). The study utilized a randomized, placebo-controlled method.

000

ADA Professional Publications @adapubs.bsky.social · 05/10/2026

🚨 New for Oct, the latest #DiabetesBio #podcast! In this episode: ✨ GIP & Muscle Microvascular Perfusion ✨ Adipose Tissue Palmitoylation & Insulin Resistance ✨ Plus "Sweet Talk" with Michael Schwartz 🎙️Listen: diabetesbio.libsyn.com 📚Read: diabetesjournals.org/diabetes/issue…

010

ADA Professional Publications @adapubs.bsky.social · 05/10/2026

In this study, PCOS was associated with increased early GDM, and adverse neonatal outcomes, underlining importance of identification, monitoring and treatment of PCOS. Read here ➡️ doi.org/10.2337/dc25-1704

Institutional infographic explaining a study on maternal and neonatal complications in pregnancy with Polycystic Ovarian Syndrome (PCOS). Sections include objectives, design and methods, results, and conclusion. Data visualized in charts indicates increased risks in pregnancies with PCOS, detailing outcomes and gestational age impacts. Concludes by comparing risks with other conditions and advising early identification of PCOS.

000

ADA Professional Publications @adapubs.bsky.social · 05/10/2026

Findings support the use of autoantibody screening and genetic testing of autoantibody negative patients as standard of care for #T1D. Read here ➡️ doi.org/10.2337/db25-1110

The image is an infographic titled "What Proportion of Antibody-Negative Type 1 Diabetes Cases Have a Nonautoimmune Etiology? A Genetics-Based Estimate." It includes sections on background, methodology, and conclusions, with a central graph showing the distribution of GRiD2 scores among various groups, including those with unknown cause and controls. The graph features a probability density curve with different shaded regions representing the groups. The infographic includes panels detailing affected siblings in the genetics consortium study. Key terms are highlighted in blue boxes, and the image concludes that a portion of diagnosed antibody-negative Type 1 diabetes cases may have nonautoimmune causes.

000

ADA Professional Publications @adapubs.bsky.social · 05/10/2026

Facing an acute diabetes burden, Asia is advancing solutions: optimizing medicines, developing novel agents, and maturing technologies, contributing to global glucose-lowering treatment innovation. Read here ➡️ doi.org/10.2337/dci26-0057

Infographic titled "Asia's Ascension in Diabetes Innovation: From Adopter to Architect." It features four main sections: "Context & Drivers," "Comprehensive Review: Dynamic Innovation Landscape," "Synthesis & Future Trajectory," and a side bubble on evolving contribution. Key elements include R&D investment, new biological insights, emerging target exploration, and frontier technologies like AI and stem cells. A flow chart highlights progression from delivery of sustained-release agents to global innovation leadership. Icons and arrows illustrate steps and connections within the innovation process.

000

ADA Professional Publications @adapubs.bsky.social · 04/10/2026

We leveraged CGM data within a robust sample of adults without diabetes to uncover the heterogeneity in dysglycemia and cardiometabolic risk that are otherwise not captured by traditional measures. Read here ➡️ doi.org/10.2337/dc26-1197

This image is a scientific chart titled "Beyond Traditional Glycemic Measures: CGM Glycemic Profiles Reveal Associations With Cardiometabolic Risk in Individuals Without Diabetes." It features multiple graphs and a radar chart comparing different glycemic profiles. The graphs show data on CGM glycemic burden and variability across different profiles. The radar chart includes metrics like fasting glucose, triglycerides, and more. The background is white with red and grey text and graphics.

000

ADA Professional Publications @adapubs.bsky.social · 04/10/2026

Time restricted eating is feasible and safe in new-onset type 1 diabetes, and may be efficacious in preserving beta-cell function in those with a higher BMI. Read here ➡️ doi.org/10.2337/doc25-0087

This image is an infographic titled "Time-Restricted Eating (TRE) in Youth With Type 1 Diabetes (T1D)." It shows a line graph with glucose values over time, including two lines for baseline and TRE. Baseline fluctuates higher than TRE. A shaded area represents the eating window from noon to 8 p.m. Summary text on the right explains that over 8 weeks, participants aged 12‑25 fasted for 16 hours daily. Results indicate improvements in C‑peptide AUC, HbA1c, and lack of adverse events. Subgroups based on BMI are shown with different percentage changes. The conclusion states TRE is feasible and safe for youth with T1D.

011

ADA Professional Publications @adapubs.bsky.social · 03/10/2026

Structured quality improvement initiative was associated with improvements in obesity care processes and weight outcomes, supporting the feasibility of scalable continuing medical education, workflow, and patient engagement tools.. Read here ➡️ doi.org/10.2337/doc26-0041

doi.org

Integrating Education and Practice Change to Improve Obesity Management: A Multisite Quality Improvement Initiative | Diabetes, Obesity, and Cardiometabolic CARE | American Diabetes Association

000

ADA Professional Publications @adapubs.bsky.social · 03/10/2026

Dual GLP-1R/GCGR agonists consistently improved cardiometabolic risk factors across randomized clinical trials and may provide metabolic benefits beyond selective GLP-1R agonists. Read here ➡️ doi.org/10.2337/dc26-1127

This image is an infographic summarizing a systematic review and meta-analysis on the cardiometabolic effects of dual GLP-1 and GCGR agonists. It includes sections on "Aims," "Methods," "Results," and "Conclusions." The aims focus on the cardiometabolic effects of dual agonists, and methods highlight database searches and trial selection criteria. Results report on studies and an association with reduced cardiometabolic risks. Conclusions state that dual agonists show favorable effects. The design is organized with sections in blue, green, purple, and yellow boxes.

000

ADA Professional Publications @adapubs.bsky.social · 03/10/2026

GDAC study analysed HbA1c-average glucose discordance and employed personalized A1c (pA1C) for better alignment. Use of pA1C may improve outcomes and reduce health disparities in diabetes. #pA1C #GDAC Read here ➡️ doi.org/10.2337/dc26-0398

This image is an infographic discussing the discordance between HbA1c and average glucose levels in individuals with diabetes. It highlights research findings, showing greater discordance particularly in Black individuals. The left graph shows HbA1c versus average glucose in lab settings, while the right graph compares this with personalized A1C, highlighting a potential 33% reduction in discordance. Text emphasizes the need for tailored A1C practices to enhance outcomes and reduce health inequities in diabetes management.

011

ADA Professional Publications @adapubs.bsky.social · 02/10/2026

Data demonstrate that Nod1 is involved in palmitate-induced β-cell dysfunction in vitro and in vivo. Read here ➡️ doi.org/10.2337/db25-0752

Diagram illustrating the effects of saturated free fatty acids on the Nod1 receptor. The Nod1 receptor activates JNK1 and IKKβ, leading to β-cell dysfunction and impaired glucose-stimulated insulin secretion.

000

ADA Professional Publications @adapubs.bsky.social · 02/10/2026

DFI in CKD is associated with a higher burden of difficult-to-treat, MDR microbial phenotypes (MDR, XDR, and MDR composite), contributing to poor clinical outcomes compared with DFI with preserved renal function. Read here ➡️ doi.org/10.2337/doc26-0056

111

ADA Professional Publications @adapubs.bsky.social · 02/10/2026

Our data suggest oral baricitinib to preserve beta cell function in type 1 diabetes needs to be taken long-term to sustain treatment benefits. Read here ➡️ doi.org/10.2337/dc26-1072

The image is an infographic titled "Do benefits of baricitinib for type 1 diabetes persist after stopping it?" It summarizes findings from the BANDIT trial, which involved 60 participants on baricitinib and 31 on a placebo. Key outcomes included improved C-peptide and decreased insulin use over 48 weeks, with some benefits lost after stopping the drug at 96 weeks. Baricitinib did not impact postprandial glucagon. Adults responded better than children. The interpretation notes clinical benefits after treatment cessation and a likely need for continuous use. Charts and graphs illustrate these findings.

000

ADA Professional Publications @adapubs.bsky.social · 02/10/2026

🚨 NEW Consensus Report: Management of Type 2 Diabetes, 2026 🚨 A holistic approach to #diabetes care must consider 1) environment/social determinants 2) complex pathophysiology 3) & long-term complications. 📚 For more, visit: doi.org/10.2337/dci26-0141

A graphic from the linked article demonstrating a holistic approach to the management of type 2 diabetes

000

ADA Professional Publications @adapubs.bsky.social · 02/10/2026

Higher insulin doses were associated with increased cardiac sympathetic predominance in adults with type 1 diabetes under free-living conditions. #T1D #Insulin Read here ➡️ doi.org/10.2337/db26-0456

This image is a research flowchart about the effects of therapeutic insulin on cardiac sympathetic predominance in people with type 1 diabetes. The diagram shows the timeline and methods used, including insulin administration and wearable heart rate sensors. Key observations noted include changes in the low-frequency/high-frequency ratio in different sleep phases with insulin dosage variations.

000

ADA Professional Publications @adapubs.bsky.social · 01/10/2026

Diabetes Care Symposium: Nonmedical Factors That Influence Diabetes Complications and Multilevel Strategies to Reduce Disparities and Improve Outcomes in the U.S. ☑️ Read here: bit.ly/4xL6Jk9 ☑️ View the collection: bit.ly/46VNGsy

This image is an infographic titled "Nonmedical Factors Exacerbating Diabetes Complications." It illustrates multilevel strategies for addressing nonmedical factors across socioecological levels. The levels include Policy, Community, Organization, and Individual, each with associated social drivers and strategies. Examples include high treatment costs and policies to reduce them, and addressing language and literacy barriers. The left side highlights established and emerging diabetes complications and disparities in disease burden.

000

ADA Professional Publications @adapubs.bsky.social · 01/10/2026

Pericytes are a significant endogenous source of hepatocyte growth factor, coupling the islet microvasculature to insulin production and glucose homeostasis. Read here ➡️ doi.org/10.2337/db26-0227

Diagram comparing embryogenesis, pregnancy, and adulthood stages in relation to β-cells. In both stages, pericytes release HGF, activating c-Met on β-cells. During embryogenesis and pregnancy, this interaction promotes β-cell expansion, shown by a red circular arrow. In adulthood, it facilitates insulin production, with Pdx1, Insa, and Slc2a2 involved in the process.

000

ADA Professional Publications @adapubs.bsky.social · 01/10/2026

Variable islet antibody (IAb) testing increases diabetes misclassification. IAb testing reclassified 13% of people with diabetes as having type 1 diabetes, 51% of whom were diagnosed >5 years prior. Read here ➡️ doi.org/10.2337/doc26-0071

This image is an infographic titled "Islet Autoantibody Ordering Patterns and Diabetes Reclassification." It displays data about 1,077 tested for diabetes classification. A pie chart shows 25% of adults were reclassified with type 1 diabetes (T1D), with details on islet autoantibodies distribution among adults and children. 13% of people tested were reclassified with T1D. Clinical characteristics of reclassified individuals include statistics on diabetes diagnosis during DKA, age, and demographics. Key terms include GAD65, IA-2, and ZnT8.

000

ADA Professional Publications @adapubs.bsky.social · 01/10/2026

🚨 A new month, a new Care on Air! Where #podcast hosts Mike & Alice discuss the latest and greatest of Diabetes Care. 🎧 diabetescareonair.libsyn.com/site 📚 diabetesjournals.org/care In this ep: ✨MACE Benefits & Tirzepatide ✨C-Peptides, Glucose, & T1D ✨ and more!

010

ADA Professional Publications @adapubs.bsky.social · 30/09/2026

Changes in specific subcellular lipid storage help explain muscle insulin sensitization following lifestyle interventions. Read here ➡️ doi.org/10.2337/db26-0239

This image is a graph with three sections labeled A, B, and C, comparing levels of TAG in whole muscle, SARC, and Mito/ER, respectively. Each section shows data for "Control," "Weight loss," and "Exercise" groups, with "Pre" and "Post" conditions. Bars display varying heights, with dotted black lines indicating significant differences and asterisks marking statistical significance.

000

ADA Professional Publications @adapubs.bsky.social · 30/09/2026

Microdosing tirzepatide vials may improve GLP-1RA access, affordability, and tolerability but also presents risks of contamination, infection, and dosing errors, warranting education and precaution. Read here ➡️ doi.org/10.2337/doc26-0083

Microdosing Instructions for Tirzepatide Approved for Chronic Weight Management in Single-Dose and Multi-Dose Vials (For Illustrative Purposes)." The table contains dosing information for tirzepatide single-dose vials and multi-dose vials, with rows and columns indicating specific dosages in milligrams. A note at the bottom states that the graphic is for illustrative purposes only and does not constitute approved guidance.

010

ADA Professional Publications @adapubs.bsky.social · 30/09/2026

New international expert recommendations on inpatient use of CGM, insulin pumps, and AID in non-critically ill hospitalised adults – covering selection criteria, clinical workflows, glycaemic metrics and targets, and more. Read here ➡️ doi.org/10.2337/dci26-0091

This image is an infographic titled “An international position statement on practical approaches for inpatient continuous glucose monitoring, insulin pumps, and automated insulin delivery systems in adults.” It features several sections: 1) Selection and education, 2) Device management, 3) Target metrics, 4) Standardized protocols, 5) CGM alarm settings, 6) Staff and patient training, 7) Technical unit training, 8) Legal matters and cost considerations, and 9) Discharge planning. It includes a chart of CGM-derived metrics and goals for non-critically ill adults, with various target glucose levels noted. The infographic is endorsed by the European Association for the Study of Diabetes (EASD), the American Diabetes Association (ADA), and The Joint British Diabetes Societies for Inpatient Care (JBDS-IP).

000

ADA Professional Publications @adapubs.bsky.social · 29/09/2026

Case Studies in Care: Continuous Subcutaneous Insulin Infusion (CSII) Therapy for Post–Roux-en-Y Dumping Syndrome in #T1D Read here ➡️ doi.org/10.2337/doc26-0033

022

ADA Professional Publications @adapubs.bsky.social · 29/09/2026

Incorporating broad societal impacts into evaluations could better capture real-world value, improve equity, and spur innovation. Read here ➡️ doi.org/10.2337/dci26-0027

The image is a conceptual framework diagram showing broader societal impacts in economic evaluations of Type 1 Diabetes technologies. It features three sections: "Current Value Assessments" on the left with icons for clinical outcomes and medical costs; "Broader Societal Impacts" in the center with icons for health, well-being, economic productivity, and social participation; "Expanded Value Assessments" on the right with icons for research, treatment access, and policy. The flow moves from left to right, indicating the transition from current to expanded evaluations.

000

ADA Professional Publications @adapubs.bsky.social · 29/09/2026

21 million real‑world longitudinal CGM data from 86,779 participants reveal clear temporal glycemic patterns. These insights can enhance CGM interpretation and personalize diabetes management. Read here ➡️ doi.org/10.2337/dc26-0886

Visual representation of a study on glycemic control using continuous glucose monitoring (CGM) data from two datasets: T1Diabetes and CP. It includes graphs illustrating weekly patterns with CGM metrics and daily patterns showing time-in-range changes. Annotations highlight increases in TIR from Tuesday to Friday, poorer control in evening and nighttime, and consistent patterns across groups.

000

ADA Professional Publications @adapubs.bsky.social · 28/09/2026

🚨NEW 🚨 Help make informed decisions on #diabetes tech ↔️ Provide initial and ongoing training device support ↔️ Review data together and make adjustments 📚 Read: "Diabetes Technology in the Primary Care Setting: An American Diabetes Association Scientific Statement" doi.org/10.2337/doci26-0005

A graph from the linked article, highlighting the role of integrating technology in a primary care setting

010

ADA Professional Publications @adapubs.bsky.social · 28/09/2026

Diabetes centers identify barriers and strategies to implement best practice care coordination with K-12 schools. Read here ➡️ doi.org/10.2337/doc26-0110

The image is an infographic titled "Despite National and International Recommendations, Evidence-Based Strategies to Support Implementation of Diabetes Care Coordination in K–12 Schools Are Needed." It includes two sections: "Health System Barriers," noting issues like "Care coordination is resource intensive" and "Reliance on antiquated systems for communication." The "School System Barriers" section highlights "Variable school policies," "Parent expectations and trust." A central box states "Mixed-methods study with 38 pediatric type 1 diabetes centers in the U.S." Below, "Proposed Implementation Strategies" are listed: "School ready-access to health records," "Use intermediaries (school nurses)," "Centrally agreed-upon standards of care," and "Billing for services."

000

ADA Professional Publications @adapubs.bsky.social · 28/09/2026

🚨 Reframing #insulin resistance as a multidimensional, tissue-specific, dynamic biological phenotype 📚 For more, read our new Expert Forum: ✨ doi.org/10.2337/dci26-0142 ✨ doi.org/10.2337/dbi26-0044 + commentary: ✨ doi.org/10.2337/dci26-0146 ✨ doi.org/10.2337/DBi26-0047

000

ADA Professional Publications @adapubs.bsky.social · 27/09/2026

A hypoglycemia prevention program designed for primary care is feasible to implement and acceptable to clinical and patient stakeholders, with evidence of improved hypoglycemia prevention efforts. Read here ➡️ doi.org/10.2337/doc25-0083

This infographic presents a study on the Hypoglycemia Prevention Program in primary care. It includes sections on design, population, outcomes, findings, and intervention. The population includes people with diabetes, focusing on primary care physicians. Outcomes note a 15% reduction in hypoglycemia events and high provider satisfaction. Findings are displayed in bar charts, indicating improved frequency of alerts and patient-provider satisfaction. The intervention highlights the use of Epic-Embedded Hypoglycemia Prevention Tools.

000

ADA Professional Publications @adapubs.bsky.social · 26/09/2026

To support accurate risk assessment and early intervention, providers should interpret mSCOFF scores with caution, particularly in racially diverse populations. Read here ➡️ doi.org/10.2337/doc26-0045

This infographic illustrates a study on equity in disordered eating screening for youth with Type 1 diabetes. It outlines four sections: 1) The need for the study, emphasizing equal screening for all. 2) Specific questions regarding differences in mSCOFF questions and outcomes based on race and puberty stages. 3) Key findings revealing varied severity and age of risk across racial groups, with a notable shift in HbA1c levels. 4) Implications stress careful result interpretation to avoid over- or under-identification, with a reminder to revise screening times. Symbols representing HbA1c, a thermometer, and diverse individuals enhance clarity.

000

ADA Professional Publications @adapubs.bsky.social · 26/09/2026

Affordable access to modern diabetes medications: Lessons from India for other countries Read here ➡️ doi.org/10.2337/dci26-0054

A flowchart titled "Making Modern Diabetes Medications Affordable and Accessible: Lessons From India for Other Countries." It shows the sequence from "Rising Diabetes Burden (LMICs)" with "Prevalence of Diabetes" and "Cost of Medicines" icons, down to "Challenges" like "High out-of-pocket costs" and "Rural access gaps." "Solutions" include "Generics with patent safeguards," "Large-scale production," "Policy and price regulation," and "Extensive public distribution." The final section, "Results," features increased affordability and accessibility of glucose-lowering drugs, illustrated with a map.

000

ADA Professional Publications @adapubs.bsky.social · 25/09/2026

Diabetes distress subtypes were not equal: emotional distress showed the strongest negative association with DDQoL, while online support buffered the impact of interpersonal distress at higher levels. Read here ➡️ doi.org/10.2337/doc25-0086

Chart titled "Predicted ADDQoL Score", showing a downward trend. The x-axis is labeled "Total Score" ranging from 2 to 6, and the y-axis is labeled "Predicted ADDQoL Score" ranging from -4 to 2. Two lines represent "Online Support" (turquoise) and "No Online Support" (red). Shaded areas around the lines indicate variance. Annotations include "ANOVA P = 0.229".

000

ADA Professional Publications @adapubs.bsky.social · 25/09/2026

findings suggest that novel therapeutic strategies targeting protein Kla modification could be significant in the clinical management of DbCM. Read here ➡️ doi.org/10.2337/db26-0432

This diagram illustrates a biological study involving db/db mice, C57BL/6 mice, and primary cardiomyocytes. It shows the process of inducing cardiac conditions through high glucose and palmitate exposure. Key pathways and proteins include Cryab, Hspb1, ERK, and MAPK, with arrows indicating activation or inhibition. The study focuses on cardiac effects such as LVFS, LVFE, and myocardial performance index.

000

ADA Professional Publications @adapubs.bsky.social · 25/09/2026

Results indicate that insurance coverage alone is insufficient to ensure adequate and equitable access to diabetes care, particularly for marginalized communities. Read here ➡️ doi.org/10.2337/dc26-2070

Map of the United States showing odds ratios by state in varying shades of blue. Darker shades indicate higher odds ratios. Notably, Maryland has an odds ratio of 1.86, Florida 1.49, and Maine 1.47. States not statistically significant are shown in gray. A legend in the bottom corner indicates the color scale and statistical significance threshold.

000

ADA Professional Publications @adapubs.bsky.social · 25/09/2026

🚨 New international statement on inpatient use of #diabetes devices With 9 key topics for practically utilizing CGMs, pumps, and AID systems in clinical settings. 📚 For more, visit: doi.org/10.2337/dci26-0091

A graphic from the linked article, illustrating an international position statement on practical approaches for inpatient use of diabetes devices

011

ADA Professional Publications @adapubs.bsky.social · 25/09/2026

⭐ 📖 Paper of the Month: Oct Islet-Targeted ZnT8 Antibodies Protect Pancreatic β-Cells From Inflammatory Stress ➡️ doi.org/10.2337/db26-0183 Articles chosen 🗓️ monthly & 🆓 online #paperofthemonth #diabetes

A call out for the journal's Paper of the Month

000

ADA Professional Publications @adapubs.bsky.social · 24/09/2026

Wearable-derived behavioral targets may be practical solutions for reducing UPF-associated diabetes risk and supporting diabetes prevention. Read here ➡️ doi.org/10.2337/db26-0395

An infographic titled "Associations of Ultraprocessed Food Intake, Wearable-Measured Lifestyle Factors, and Genetic Susceptibility With Incident Type 2 Diabetes." It includes sections on study overview, independent associations, lifestyle-gene analysis, and joint analysis. It features Biobank data with 56,964 participants. Graphs compare associations of ultraprocessed food intake with diabetes, moderated by physical activity and genetic risk levels. Conclusion highlights a positive link between ultraprocessed food intake and type 2 diabetes risk.

000

ADA Professional Publications @adapubs.bsky.social · 24/09/2026

Calorie-restricted CRD, DASH, and LPBD achieved similar weight loss and urate lowering. DASH improved adherence and preserved lean mass; early flare risk warrants attention. Read here ➡️ doi.org/10.2337/dc26-1241

Study overview infographic showing findings on carbohydrate-restricted diet (CRD) versus DASH diet and low-purine balanced diet (LPBD) in adults with hyperuricemia. Four sections include: Study Overview with a schematic of shared calorie restriction; Primary Finding showing a graph with no significant global differences; Acute Phase displaying transient blood urate levels; and Adherence and Body Composition with a box plot highlighting better adherence and less lean mass loss with DASH diet.

000

ADA Professional Publications @adapubs.bsky.social · 24/09/2026

This study within All of Us showed that most adults taking GLP-1 receptor agonists did not meet physical activity guidelines, highlighting the need for targeted interventions to increase activity 🏃 🏋️ Read here ➡️ doi.org/10.2337/doc26-0062

000